Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Harmony Biosciences Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony’s narcolepsy drug, Wakix (pitolisant). The report raised numerous concerns related to patient health, drug efficacy, and trial reliability, as well as allegations the Company engaged in price-gouging, false advertising, and a significant off-label and physician kickback scheme. Following this news, Harmony’s stock price fell by $10.70 per share to close at $30.80 per share.
In order to be eligible to join the HRMY class action lawsuit, you must have incurred a loss on shares of Harmony Biosciences Holdings, Inc. purchased during the class period listed above.
TOP
